InvestorsHub Logo
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

Re: None

Tuesday, 06/25/2013 11:40:10 AM

Tuesday, June 25, 2013 11:40:10 AM

Post# of 286
Seattle Genetics enters into new antibody-drug conjugate collaboration with Bayer (BAYRY) (SGEN) 29.90 : Co announced that it has entered into a new antibody-drug conjugate collaboration with Bayer HealthCare (BAYRY). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 mln for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics is also eligible to receive up to ~$500 mln in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products under the collaboration.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SGEN News